|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 9/00 | (2006.01) |
| A61K 9/19 | (2006.01) | ||
| A61K 38/00 | (2006.01) | ||
| A61K 38/17 | (2006.01) | ||
| A61M 5/178 | (2006.01) | ||
| C07K 14/47 | (2006.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2944306 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15169936.0 |
| Date of filing the European patent application | 2007-06-14 | |
| (97) | Date of publication of the European application | 2015-11-18 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-27 |
| (46) | Date of publication of the claims translation | 2021-02-25 |
| (30) | Number | Date | Country code |
| 814484 P | 2006-06-16 | US |
| (72) |
GRAHAM, Kenneth S., US
FRYE, Kelly, US
FURFINE, Eric, US
DIX, Daniel, US
|
| (73) |
REGENERON PHARMACEUTICALS, INC.,
777 Old Saw Mill River Road, Tarrytown, NY 10591-6707,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | VFGF antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu |
| VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION |
| Payment date | Validity (years) | Amount | |
| 2025-05-20 | 19 | 347.00 EUR |
| 2026-06-14 |